Table 1 Association of GNIP1 expression levels with clinicopathologic characteristics in NSCLC
Clinicopathologic | Levels | GNIP1 expression | p-value | |
|---|---|---|---|---|
Characteristics | Â | Low expression group | High expression of group | Â |
n | Â | 267 | 268 | 0.158 |
Age, n (%) | ≤ 65 | 137 (51.3%) | 118 (44.0%) | |
> 65 | 123 (46.1%) | 138 (51.5%) | ||
Unknown | 7 (2.6%) | 12 (4.5%) | ||
Race, n (%) | Asian | 2 (0.7%) | 5 (1.9%) | 0.479 |
Black or African American | 26 (9.7%) | 29 (10.8%) | ||
White | 205 (76.8%) | 201 (75.0%) | ||
Unknown | 34 (12.7%) | 33 (12.3%) | ||
Gender, n (%) | Female | 154 (57.7%) | 132 (49.3%) | 0.062 |
Male | 113 (42.3%) | 136 (50.7%) | ||
Unknown | 0 | 0 | ||
Smoker, n (%) | No | 41 (15.4%) | 34 (12.7%) | 0.465 |
Yes | 220 (82.4%) | 226 (84.3%) | ||
Unknown | 6 (2.2%) | 8 (3.0%) | ||
T stage, n (%) | T1 | 90 (33.7%) | 85 (31.7%) | 0.636 |
T2 | 147 (55.1%) | 142 (53.0%) | ||
T3 | 21 (7.9%) | 28 (10.4%) | ||
T4 | 8 (3.0%) | 11 (4.1%) | ||
Unknown | 1 (0.3%) | 2 (0.7%) | ||
N stage, n (%) | N0 | 188 (70.4%) | 160 (59.7%) | 0.018* |
N1 | 42 (15.7%) | 53 (19.8%) | ||
N2 | 27 (10.1%) | 47 (17.5%) | ||
N3 | 1 (0.4%) | 1 (0.4%) | ||
Unknown | 9 (3.4%) | 7 (2.6%) | ||
M stage, n (%) | M0 | 194 (72.7%) | 167 (62.3%) | 0.461 |
M1 | 11 (4.1%) | 14 (5.2%) | ||
Unknown | 62 (23.2%) | 87 (32.5%) | ||
Pathologic stage, n (%) | Stage I | 157 (58.8%) | 137 (51.1%) | 0.019* |
Stage II | 65 (24.3%) | 58 (21.6%) | ||
Stage III | 29 (10.9%) | 55 (20.5%) | ||
Stage IV | 12 (4.5%) | 14 (5.2%) | ||
Unknown | 4 (1.5%) | 4 (1.5%) | ||
Primary therapy outcome, n (%) | PD | 36 (13.5%) | 35 (13.1%) | 0.959 |
SD | 17 (6.4%) | 20 (7.5%) | ||
PR | 3 (1.1%) | 3 (1.1%) | ||
CR | 169 (63.3%) | 163 (60.8%) | ||
Unknown | 42 (15.7%) | 47 (17.5%) | ||